27.15

1.76% 0.47

Acadia Pharmaceuticals Inc (ACAD)

Overview News Price History Option Chain Financials Why ACAD Down? Discussions Forecast

Acadia Pharmaceuticals Inc stock is traded at $27.15, with a volume of 1.27M. It is up +1.76% in the last 24 hours and up +12.52% over the past month. Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.

Previous Close:

$26.68

Open:

$26.75

24h Volume:

1.27M

Relative Volume:

0.67

Market Cap:

$4.59B

Revenue:

$890.53M

Net Income/Loss:

$30.57M

P/E Ratio:

150.83

EPS:

0.18

Net Cash Flow:

$80.53M

1W Performance:

-1.06%

1M Performance:

+12.52%

6M Performance:

+24.89%

1Y Performance:

+57.30%

1-Day Range:

$26.42

$27.28

1-Week Range:

$26.38

$27.73

52-Week Range:

$13.40

$27.73

Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile

Name

Acadia Pharmaceuticals Inc

Sector

Healthcare (1123)

Industry

Biotechnology (627)

Phone

858-558-2871

Address

12830 EL CAMINO REAL, SAN DIEGO

Employee

654

Twitter

@acadiapharma

Next Earnings Date

2024-11-06

Latest SEC Filings

ACAD's Discussions on Twitter

Compare ACAD with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ACAD Acadia Pharmaceuticals Inc	27.15	4.51B	890.53M	30.57M	80.53M	0.18
VRTX Vertex Pharmaceuticals Inc	452.04	113.14B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	741.29	78.49B	14.25B	4.58B	3.88B	41.77
ARGX Argen X Se Adr	877.94	54.76B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	397.55	54.51B	3.21B	43.57M	221.36M	0.2405
INSM Insmed Inc	197.01	41.64B	447.02M	-1.18B	-906.14M	-6.1812

Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-21-25	Initiated	Citigroup	Buy
May-21-25	Upgrade	Deutsche Bank	Hold → Buy
Feb-11-25	Initiated	Deutsche Bank	Hold
Jan-03-25	Downgrade	Guggenheim	Buy → Neutral
Oct-10-24	Resumed	Raymond James	Mkt Perform
Aug-07-24	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Jun-27-24	Initiated	BMO Capital Markets	Outperform
Mar-12-24	Downgrade	Mizuho	Buy → Neutral
Mar-12-24	Reiterated	Needham	Buy
Jan-30-24	Initiated	Robert W. Baird	Outperform
Jan-24-24	Upgrade	Needham	Hold → Buy
Dec-19-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Dec-14-23	Downgrade	Deutsche Bank	Buy → Hold
Dec-13-23	Initiated	Citigroup	Buy
Dec-12-23	Initiated	Deutsche Bank	Buy
Nov-06-23	Upgrade	Mizuho	Neutral → Buy
Oct-17-23	Initiated	UBS	Buy
Oct-10-23	Upgrade	JP Morgan	Neutral → Overweight
Jan-03-23	Upgrade	Guggenheim	Neutral → Buy
Nov-04-22	Downgrade	Goldman	Neutral → Sell
Nov-01-22	Initiated	Loop Capital	Hold
Aug-08-22	Downgrade	Citigroup	Buy → Neutral
Aug-05-22	Downgrade	Citigroup	Buy → Neutral
Jun-21-22	Downgrade	Jefferies	Buy → Underperform
Jun-16-22	Upgrade	Jefferies	Hold → Buy
Mar-16-22	Upgrade	Canaccord Genuity	Hold → Buy
Feb-09-22	Upgrade	H.C. Wainwright	Neutral → Buy
Jan-05-22	Upgrade	Citigroup	Neutral → Buy
Dec-21-21	Downgrade	Guggenheim	Buy → Neutral
Nov-01-21	Upgrade	Guggenheim	Neutral → Buy
Oct-14-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Sep-23-21	Resumed	Needham	Hold
Jun-10-21	Initiated	Berenberg	Hold
Apr-07-21	Downgrade	H.C. Wainwright	Buy → Neutral
Apr-06-21	Downgrade	Canaccord Genuity	Buy → Hold
Apr-06-21	Downgrade	Goldman	Buy → Neutral
Apr-06-21	Downgrade	Jefferies	Buy → Hold
Apr-06-21	Downgrade	Mizuho	Buy → Neutral
Apr-05-21	Downgrade	Raymond James	Outperform → Mkt Perform
Mar-10-21	Downgrade	BofA Securities	Buy → Neutral
Mar-09-21	Downgrade	Citigroup	Buy → Neutral
Mar-09-21	Downgrade	Guggenheim	Buy → Neutral
Mar-09-21	Reiterated	H.C. Wainwright	Buy
Mar-09-21	Downgrade	Raymond James	Strong Buy → Outperform
Mar-09-21	Downgrade	Stifel	Buy → Hold
Dec-16-20	Initiated	Mizuho	Buy
Nov-16-20	Upgrade	Raymond James	Outperform → Strong Buy
Aug-25-20	Initiated	Raymond James	Outperform
Aug-20-20	Initiated	Morgan Stanley	Overweight
Jul-07-20	Upgrade	Stifel	Hold → Buy
Apr-16-20	Initiated	Jefferies	Buy
Mar-31-20	Upgrade	Goldman	Neutral → Buy
Mar-06-20	Initiated	Citigroup	Buy
Dec-16-19	Initiated	Guggenheim	Buy
Oct-24-19	Initiated	Oppenheimer	Perform
Oct-01-19	Initiated	RBC Capital Mkts	Outperform
Sep-13-19	Upgrade	SVB Leerink	Mkt Perform → Outperform
Sep-10-19	Upgrade	Canaccord Genuity	Hold → Buy
Jul-23-19	Reiterated	Needham	Buy
Dec-10-18	Initiated	Canaccord Genuity	Hold
Sep-21-18	Upgrade	Piper Jaffray	Neutral → Overweight
Aug-09-18	Reiterated	Stifel	Hold
Aug-07-18	Initiated	Stifel	Hold
Aug-06-18	Downgrade	Piper Jaffray	Overweight → Neutral
Oct-06-17	Resumed	Goldman	Neutral

View All

Acadia Pharmaceuticals Inc Stock (ACAD) Latest News

Dec 13, 2025

TFG Asset Management GP Ltd Has $3.48 Million Stake in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat

Dec 13, 2025

Eventide Asset Management LLC Trims Holdings in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat

Dec 13, 2025

Birchview Capital LP Sells 75,600 Shares of ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat

Dec 13, 2025

Dec 12, 2025

FDA approves powder formulation of trofinetide for Rett syndrome - Contemporary Pediatrics

Dec 12, 2025

FDA Approves New Formulation for Acadia Pharmaceuticals' (ACAD) Rett Syndrome Treatment - GuruFocus

Dec 12, 2025

Acadia Pharmaceuticals Announces FDA Approval of DAYBUE® STIX (trofinetide) for Oral Solution, a New Powder Formulation of Trofinetide for the Treatment of Rett Syndrome - The Joplin Globe

Dec 12, 2025

STIX (trofinetide) for Oral Solution, a New Powder Formulation of Trofinetide for the Treatment of Rett Syndrome - Business Wire

Dec 12, 2025

OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Takes $928,000 Position in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat

Dec 12, 2025

Dec 11, 2025

Acadia Pharmaceuticals stock price target raised by Stifel to $25 from $24 - Investing.com Canada

Dec 11, 2025

Should ACADIA’s Earnings Beat and Conference Highlights Require Action From ACADIA Pharmaceuticals (ACAD) Investors? - Sahm

Dec 11, 2025

Stifel Nicolaus Issues Positive Forecast for ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock Price - MarketBeat

Dec 11, 2025

Stifel Maintains Hold Rating and Raises Price Target for ACAD to $25.00 | ACAD Stock News - GuruFocus

Dec 11, 2025

Dec 10, 2025

What drives ACADIA Pharmaceuticals Inc stock priceReal Estate Investment Trusts & Affordable Market Investment - earlytimes.in

Dec 10, 2025

Dec 08, 2025

Norges Bank Invests $31.68 Million in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat

Dec 08, 2025